The diagnostic performance of urinary free cortisol is better than the cortisol:cortisone ratio in detecting de novo Cushing's syndrome: the use of a LC-MS/MS method in routine clinical practice.

OBJECTIVE The Endocrine Society Clinical Guidelines recommend measuring 24-h urinary free cortisol (UFF) levels using a highly accurate method as one of the first-line screening tests for the diagnosis of Cushing's Syndrome (CS). We evaluated the performance of UFF, urinary free cortisone (UFE), and the UFF:UFE ratio, measured using a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. SUBJECTS AND METHODS The LC-MS/MS was used to analyze UFF and UFE levels in 43 surgically confirmed CS patients: 26 with Cushing's disease (CD, 16 de novo and ten recurrences), 11 with adrenal CS and six with ectopic CS; 22 CD patients in remission; 14 eu-cortisolemic CD patients receiving medical therapy; 60 non-CS patients; and 70 healthy controls. Sensitivity and specificity were determined in the combined groups of non-CS patients, healthy controls, and CD in remission. RESULTS UFF>170 nmol/24 h showed 98.7% specificity and 100% sensitivity for de novo CS, while sensitivity was 80% for recurrent CD patients, who were characterized by lower UFF levels. The UFF:UFE and UFF+UFE showed lower sensitivity and specificity than UFF. Ectopic CS patients had the highest UFF and UFF:UFE levels, which were normal in the CD remission patients and in those receiving medical therapy. CONCLUSIONS Our data suggest high diagnostic performance of UFF excretion measured using LC-MS/MS, in detecting de novo CS. UFF:UFE and UFF+UFE assessments are not useful in the first step of CS diagnosis, although high levels were found to be indicative of ectopic CS.

[1]  C. Scaroni,et al.  Cortisol and cortisone ratio in urine: LC-MS/MS method validation and preliminary clinical application , 2014, Clinical chemistry and laboratory medicine.

[2]  A. Colao,et al.  High variability in baseline urinary free cortisol values in patients with Cushing’s disease , 2013, Clinical endocrinology.

[3]  A. Fassina,et al.  Predicting late recurrence in surgically treated patients with Cushing's disease , 2013, Clinical endocrinology.

[4]  G. Occhi,et al.  Performance of salivary cortisol in the diagnosis of Cushing's syndrome, adrenal incidentaloma, and adrenal insufficiency. , 2013, European journal of endocrinology.

[5]  B. Keevil,et al.  Mass spectrometry for the endocrine clinic – much to digest , 2013, Clinical endocrinology.

[6]  E. Papini,et al.  Screening of Cushing's syndrome in outpatients with type 2 diabetes: results of a prospective multicentric study in Italy. , 2012, The Journal of clinical endocrinology and metabolism.

[7]  J. Bertherat,et al.  Sequential hormonal changes in 21 patients with recurrent Cushing's disease after successful pituitary surgery. , 2011, European journal of endocrinology.

[8]  S. Rainbow,et al.  Detection of synthetic glucocorticoids by liquid chromatography-tandem mass spectrometry in patients being investigated for Cushing's syndrome , 2011, Annals of clinical biochemistry.

[9]  F. Iavarone,et al.  A simple liquid chromatography-tandem mass spectrometry method for urinary free cortisol analysis: suitable for routine purpose , 2010, Clinical chemistry and laboratory medicine.

[10]  S. Tam,et al.  Improved liquid chromatography–tandem mass spectrometry method in clinical utility for the diagnosis of Cushing’s syndrome , 2010, Analytical and bioanalytical chemistry.

[11]  M. Cooper,et al.  11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. , 2009, The Journal of clinical endocrinology and metabolism.

[12]  S. Grundy,et al.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.

[13]  G. Arnaldi,et al.  Approach to the patient with possible Cushing's syndrome. , 2009, The Journal of clinical endocrinology and metabolism.

[14]  N. Valli,et al.  Late-night salivary cortisol for diagnosis of overt and subclinical Cushing's syndrome in hospitalized and ambulatory patients. , 2009, The Journal of clinical endocrinology and metabolism.

[15]  J. Bertherat,et al.  Midnight salivary cortisol determination for assessing the outcome of transsphenoidal surgery in Cushing's disease. , 2008, The Journal of clinical endocrinology and metabolism.

[16]  V. Montori,et al.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. , 2008, The Journal of clinical endocrinology and metabolism.

[17]  I. Chiodini,et al.  Subclinical Hypercortisolism among Outpatients Referred for Osteoporosis , 2007, Annals of Internal Medicine.

[18]  P. Stiefel,et al.  Role of ketoconazole treatment in urinary-free cortisol-to-cortisone and tetrahydrocortisol-to-tetrahydrocortisone ratios in nonectopic cushing’s syndrome , 2002, Endocrine.

[19]  Tatsuhide Inoue,et al.  [Ectopic ACTH syndrome]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[20]  Robert L. Taylor,et al.  Validation of a high-throughput liquid chromatography-tandem mass spectrometry method for urinary cortisol and cortisone. , 2002, Clinical chemistry.

[21]  C. Shackleton,et al.  Urinary free cortisone and the assessment of 11β‐hydroxysteroid dehydrogenase activity in man , 1996, Clinical endocrinology.